Patients with breast cancer exhibiting HER2 IHC 1+ or IHC 2+/ISH non-amplified may be eligible for targeted treatment with cytotoxic drugs (IHC 0 is not an eligibility criterion)” [11]. Here, ERBB2 is linked to breast cancer.